An Open-Label, Single-Arm Pilot Study in Patients with Moderate to Severe Plaque-Type Psoriasis treated with Mesalazine
Tarun Narang, Sanjeev Handa
Citation Information :
Narang T, Handa S. An Open-Label, Single-Arm Pilot Study in Patients with Moderate to Severe Plaque-Type Psoriasis treated with Mesalazine. J Postgrad Med Edu Res 2014; 48 (1):24-26.
Handa S, Narang T. An Open-Label, Single-Arm Pilot Study in Patients with Moderate to Severe Plaque-Type Psoriasis treated with Mesalazine. J Postgrad Med Edu Res 2014;48(1):24-26.
Increased concentrations of nonesterified arachidonic acid, 12 L-hydroxy-5, 8, 10, 14-eicosatetraenoic acid, prostaglandin E2 and prostaglandin F2 alpha in epidermis of psoriasis. Proc Natl Acad Sci USA 1975;72:5130-5134.
The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol 1984;83:70-73.
Sulfasalazine: a potential psoriasis therapy? J Am Acad Dermatol 1989;20: 797-800.
Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 1990;126: 487-493.
The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998;25:1957-1961.
Felix-Davies D, Bacon PA. Treatment of psoriatic arthritis with sulfasalazine: a 1-year open study. Clin Rheumatol 1988;7:372-377.
Psoriasis treatment with 5-Aminosalicylic acid. Int J Dermatol 1994;33: 573-575.
Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J Invest Dermatol 1990;95:50-54.
Mesalazine as a new therapeutic option for chronic idiopathic urticaria. J Dermatolog Treat 2011 Jul 19.
Role of interferon-gamma in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch Dermatol 1988;124:1835-1843.
Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 2001;144:583-586.
